Krystal Biotech, Inc.
Price Action
Technical Summary
EMERGING TRENDKrystal Biotech, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 80), indicating clear outperformance against the broad market. Earnings growth of 53% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $270.89 | +6.65% | ABOVE |
| 50 SMA | $262.97 | +9.86% | ABOVE |
| 100 SMA | $263.97 | +9.44% | ABOVE |
| 150 SMA | $242.86 | +18.95% | ABOVE |
| 200 SMA | $219.81 | +31.43% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is KRYS in an uptrend right now?
KRYS has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is KRYS overbought or oversold?
KRYS's RSI (14) is 62. The stock is in neutral territory, neither overbought nor oversold.
Is KRYS outperforming the market?
KRYS has a Relative Strength (RS) Rating of 80 out of 99. Yes, KRYS is a market leader, outperforming 80% of all stocks over the past 12 months.
Where is KRYS in its 52-week range?
KRYS is trading at $288.89, which is 95% of its 52-week high ($303.00) and 92% above its 52-week low ($122.80).
How volatile is KRYS?
KRYS has a Beta of 1.12 and 52-week volatility of 41%. It's more volatile than the S&P 500 - expect bigger swings.